Change over period: —
NSE · INDOCO
INDOCO REM
-11.6% from the 52-week high · +47.6% above the low
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra and currently employs 6,101 full-time employees. The company went IPO on 2005-01-07. The firm is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The firm caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.
The short version. INDOCO REM reported revenue of ₹520 crore for Sep 2026, up 7.2% from a year earlier. Net profit was ₹18 crore. Return on equity was -10.1% in Mar 2026. Promoter holding was 58.92% in Sep 2026, up 0.12 points over 8 quarters.
1 · The price
How has the stock traded?
INDOCO REM trades 11.6% below its 52-week high and 47.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹520 cr.
5.1 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 520 | 468 | 476 | 445 | 485 | 438 | 390 | 411 |
| Net profit | 18 | 65 | -22 | -30 | -8 | -36 | -40 | -26 |
| Net margin % | 3.5 | 13.9 | -4.5 | -6.7 | -1.6 | -8.2 | -10.4 | -6.4 |
| EPS (₹) | 1.99 | 7.04 | -2.34 | -3.23 | -0.86 | -3.88 | -4.38 | -2.86 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | 1845 | 1665 | 1817 | 1669 | 1541 | 1242 | 1107 |
| Net profit | -95 | -74 | 98 | 142 | 155 | 93 | 24 |
| Net margin % | -5.2 | -4.4 | 5.4 | 8.5 | 10.0 | 7.5 | 2.2 |
| EPS (₹) | -10.31 | -7.99 | 10.68 | 15.44 | 16.8 | 10.1 | 2.62 |
3 · The quality
How well does it turn capital into profit?
Return on equity was -10.1% in Mar 2026; debt to equity is 1.10.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | -10.1 | -7.2 | 8.9 | 13.8 |
| Return on capital % | 1.0 | -0.5 | 11.3 | 17.7 |
| EBITDA margin % | 7.7 | 6.3 | 14.5 | 17.3 |
| Net margin % | -5.1 | -4.4 | 5.4 | 8.5 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 3.4% | 8.2% |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Up 0.12 pts over 8 quarters.
Up 0.39 pts over 8 quarters.
Down 2.26 pts over 8 quarters.
+1 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 58.8 | 58.9 | 58.9 | 58.9 | 58.9 | 58.86 | 58.86 | 58.92 | +0.12 |
| FII | 1.25 | 1.24 | 1.22 | 1.25 | 1.1 | 0.94 | 1.27 | 1.64 | +0.39 |
| DII | 18.9 | 18.75 | 18.96 | 18.16 | 18.15 | 18.15 | 17.68 | 16.64 | -2.26 |
| Public | 21.03 | 21.02 | 20.83 | 21.6 | 21.77 | 21.9 | 22.04 | 22.66 | +1.63 |
Mutual fund holdings · Oct 2026
9 schemes hold this stock
8 the month before.
- DSP Healthcare Fund1.81% of NAV
- DSP Multi Cap Fund0.57% of NAV
- HDFC Value Fund0.39% of NAV
- NIPPON INDIA PHARMA FUND0.38% of NAV
- ICICI Prudential Healthcare Fund0.29% of NAV
- quant Small Cap Fund0.26% of NAV
- NIPPON INDIA SMALL CAP FUND0.07% of NAV
- Bandhan BSE Healthcare Index Fund0.05% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for INDOCO REM are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about INDOCO REM
What is the INDOCO REM share price?
INDOCO REM (INDOCO) last closed at ₹233.08, down 3.69% on the day. Its 52-week range is ₹164.00 to ₹273.77.
What is the market cap of INDOCO REM?
INDOCO REM has a market capitalisation of about ₹2,226 crore. Its price-to-earnings ratio is 68.1.
How are INDOCO REM's latest results?
INDOCO REM reported revenue of ₹520 crore for Sep 2026, up 7.2% from a year earlier. Net profit was ₹18 crore. Return on equity was -10.1% in Mar 2026. Promoter holding was 58.92% in Sep 2026, up 0.12 points over 8 quarters.
Who owns INDOCO REM?
As of Sep 2026, shareholding was: Promoter 58.92%, FII 1.64%, DII 16.64%, Public 22.66%.
How many mutual funds hold INDOCO REM?
9 mutual fund schemes held INDOCO REM in October 2026. That compares with 8 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 04 Sep 2025 · Final Dividend - Rs. 0.2
- 19 Sep 2024 · Final Dividend - Rs. 1.5
- 18 Sep 2023 · Final Dividend - Rs. 2.25
- 14 Sep 2022 · Final Dividend - Rs. 1.5
- 14 Sep 2022 · Special Dividend - Rs. 0.75
- 17 Sep 2021 · Final Dividend - Rs. 1.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.